Abeona Therapeutics, Inc.
(NASDAQ : ABEO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
0.59%138.782.8%$480.45m
ZTSZoetis, Inc. Class A
-1.17%93.801.9%$227.54m
MYLMylan N.V.
-1.22%31.713.2%$143.78m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
-2.33%17.602.1%$138.25m
TXMDTherapeuticsMD, Inc.
-0.33%5.9725.3%$16.63m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
-1.13%35.992.0%$9.90m
TAROTaro Pharmaceutical Industries Ltd.
-0.19%104.266.4%$7.10m
LFVNLifeVantage Corporation
-0.38%15.933.3%$3.40m
ABEOAbeona Therapeutics, Inc.
0.30%6.707.8%$2.68m
KINKindred Biosciences, Inc.
0.83%10.910.3%$2.32m
PETXAratana Therapeutics, Inc.
-0.83%4.368.5%$1.94m
JAGXJaguar Animal Health, Inc.
-1.79%0.249.8%$0.07m
CPHIChina Pharma Holdings, Inc.
-2.61%0.260.1%$0.04m

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Dallas, TX.